CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open account
☰
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open account
✖

EURUSD retests 119 as Europe punts Astrazeneca decision to Thursday

Article By: ,  Head of Market Research
March 16, 2021 12:41 PM

EUR/USD retests 1.19 as Europe punts Astrazeneca decision to Thursday

Stated simply, the European Medicines Association is stuck between a rock and a hard place: COVID cases are rising throughout the continent, but the much-needed AstraZeneca vaccine has been called into question over a couple of reported cases of dangerous blood clots. With many countries across Europe already struggling to overcome logistical hurdles and vaccine skepticism among the populace, the concerns about vaccine side effects are the last thing the continent needs.

This morning, the European Medicines Association delayed its scheduled decision on whether to ban the AstraZeneca vaccine to Thursday as it evaluates the blood clots on a case-by-case basis. Reading the tea leaves, the group appears to be leaning against an outright ban, with various representatives stating that there is “no evidence” linking the blood clots to the vaccine, that side effects have occurred at a rate “no higher than the number seen in the general population,” that the “vaccine’s benefits continue to outweigh its risks,” and that any changes to current recommendations are “unlikely.”

With the market hyper-focused on the timelines for economic recoveries, Europe is at least a month or two behind the US and UK in vaccinating its population, which means it’s likely a couple months behind on reopening its economy fully. The lack of buy-in for additional fiscal stimulus, unlike we’ve seen in the US this week, could further delay a full economic recovery on the continent.

EUR/USD technical analysis

In any event, the euro is the worst-performing major currency on the day, with the delayed vaccine decision playing a major role in the move. The world’s most widely-traded currency pair broke down to a nearly 1-week low below 1.1910, triggering a number of short-term stop sell orders and driving EUR/USD below 1.1900 as of writing.

Source: TradingView, StoneX

Moving forward, the pair’s near-term technical bias will remain to the downside as long as rates hold below 1.1910, and more broadly, it would take a move back above 1.2000 to convince bulls that the longer-term uptrend has resumed. To the downside, bears may look to target the year-to-date low at 1.1835 next.

Learn more about forex trading opportunities.


StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. CFD and Forex Trading are leveraged products and your capital is at risk. They may not be suitable for everyone. Please ensure you fully understand the risks involved by reading our full risk warning.

City Index is a trading name of StoneX Financial Ltd. Head and Registered Office: 1st Floor, Moor House, 120 London Wall, London, EC2Y 5ET. StoneX Financial Ltd is a company registered in England and Wales, number: 05616586. Authorised and regulated by the Financial Conduct Authority. FCA Register Number: 446717.

City Index is a trademark of StoneX Financial Ltd.

The information on this website is not targeted at the general public of any particular country. It is not intended for distribution to residents in any country where such distribution or use would contravene any local law or regulatory requirement.

© City Index 2024